European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 32-39 , January 2008

High prevalence of cardiovascular risk in patients with toxic oil syndrome: A comparative study using the general Spanish population

  • María Luisa García de Aguinaga

      Affiliations

    • Toxic Oil Syndrome Research Unit, Rare Diseases Research Institute, Instituto de Salud Carlos III, Spain
    • ,
  • Manuel Posada de la Paz

      Affiliations

    • Toxic Oil Syndrome Research Unit, Rare Diseases Research Institute, Instituto de Salud Carlos III, Spain
    • Corresponding Author InformationCorresponding author. Instituto de Salud Carlos III. Pabellón 11-IIER, Calle Sinesio Delgado, 6. 28029. Madrid, Spain. Tel.: +34 91 8222044; fax: +34 91 3877895.
    • ,
  • Eva Estirado de Cabo

      Affiliations

    • Toxic Oil Syndrome Research Unit, Rare Diseases Research Institute, Instituto de Salud Carlos III, Spain
    • ,
  • María del Mar Plaza Cano

      Affiliations

    • Toxic Oil Syndrome Research Unit, Rare Diseases Research Institute, Instituto de Salud Carlos III, Spain
    • ,
  • Carmen Suárez Álvarez

      Affiliations

    • Toxic Oil Syndrome Research Unit, Rare Diseases Research Institute, Instituto de Salud Carlos III, Spain
    • ,
  • Beatriz Braun Saro

      Affiliations

    • Toxic Oil Syndrome Research Unit, Rare Diseases Research Institute, Instituto de Salud Carlos III, Spain
    • ,
  • Ignacio Abaitua Borda

      Affiliations

    • Toxic Oil Syndrome Research Unit, Rare Diseases Research Institute, Instituto de Salud Carlos III, Spain
    • ,
  • Rafael Gabriel Sánchez

      Affiliations

    • Hospital Universitario La Paz, Madrid, Spain
    • ,
  • Francisco Javier Barbado Hernández

      Affiliations

    • Hospital Universitario La Paz, Madrid, Spain

Received 18 December 2006 ,Accepted 20 April 2007.

References 

  1. Murray CJL, López AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504
  2. Beaglehole R. International trends in coronary heart disease mortality, morbidity and risk factors. Epidemiol Rev. 1990;12:1–15
  3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  4. Tunstall-Pedoe H, Kuulasmaa K, Mahönen M, Tolonen H, Ruokokoski E, Amouyel P for the WHO MONICA project. Contribution of trends in survival and coronary event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet. 1999;353:1547–1557
  5. Menotti A, Lanti M, Puddu E, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart. 2000;84:238–244
  6. Masia R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. J Epidemiol Community Health. 1998;52:707–715
  7. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  8. The DECODE Study Group (Gabriel R, as a member of the DECODE Study Group).. Comparison of three different definitions for the metabolic syndrome in non-diabetic Europeans. Br J Diabetes Vasc Dis. 2005;5:161–168
  9. . Grandjean P, Tarkowsky S. Review of investigations and findings. In: World Health Organization. RofE, editor. Toxic Oil Syndrome: Mass food poisoning in Spain. 1st ed Copenhagen: WHO, Regional Office for Europe; 1984:3–16.
  10. Posada de la Paz M, Philen RM, Abaitua Borda I. Toxic Oil Syndrome: the perspective after 20 years. Epidemiol Rev. 2001;23(2):231–247
  11. Calaf RE, Pena J, Paytubi S, Blount BC, Posada de la Paz M, Gelpi E, et al. Determination of aniline derivatives in oils related to the toxic oil syndrome by atmospheric pressure ionization-tandem mass spectrometry. Anal Chem. Aug 15 2001;73(16):3828–3837
  12. Ruiz-Méndez MV, Posada de la Paz M, Abian J. Storage time and deodorization temperature influence the formation of aniline-derived compounds in denatured rapeseed oils. Food chem toxicol. 2001;39(1):91–96
  13. James TN, Posada de la Paz M, Abaitua Borda I. Histologic abnormalities of large and small coronary arteries, neural structures, and the conduction system of the heart found in postmortem studies of individuals dying from the toxic oil syndrome. See comments. Am Heart J. 1991;121(3 Pt 1):803–815
  14. Martínez Tello FJ, Tellez I. Extracardiac vascular and neural lesions in the toxic oil syndrome. J Am Coll Cardiol. 1991;18(4):1043–1047
  15. Gelpi E, Posada de la Paz M, Terracini B for the WHO/CISAT Scientific Committee for the Toxic Oil Syndrome. The Spanish Toxic Oil Syndrome: epidemiological, immunological and toxicological knowledge twenty years after its occurrence. Environ Health Perspect. 2002;110(5):457–464
  16. Gallardo S, Pozo V, del Cardaba B. Immunological basis of Toxic Oil Syndrome. Toxicology. 1994;93:289–299
  17. Ladona MG, Izquierdo Martínez M, Posada de la Paz M, Torre Coral Ampurdanés R, de la Segura J, Sanz EJ. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish Toxic Oil Syndrome. Environ Health Perspect. 2001;109:369–375
  18. Colomé N, Prieto MR, Carrascal M, Posada M, Gelpí E, Abian J. Determination of protein markers in human serum: analysis of protein expression in toxic oil syndrome Studies. Proteomics. 2004;4:303–315
  19. Cardaba B, Pozo V, Gallardo S, Palomino P, Posada M, Lahoz C. Toxic Oil Syndrome: genetic approaches in the understanding of Toxic Oil Syndrome. Toxicol Lett. Feb 8 2006;161(1):83–88
  20. Gómez de la Cámara A, Posada de la Paz M, Plaza Cano M, et al. Clinical aspects. In:  Terraccini B editors. World Health Organization. Toxic Oil Syndrome, Ten Years of Progress. Copenhagen: WHO, Regional Office for Europe; 2004;p. 25–35
  21. Posada de la Paz M, Philen RM, Gerr F, et al. Neurologic outcomes of Toxic Oil Syndrome patients 18 years after the epidemic. Environ Health Perspect. 2003;111(10):
  22. Saenz Calvo A, García del Valle M, Cordón Rodríguez E, Izquierdo Martínez M, Ausejo Segura M, Rojas Hidalgo E. Hiperglucemia en el Síndrome del aceite tóxico (Hyperglycemia in the toxic oil syndrome). Aten Prim. 1995;15:542–546
  23. Gómez de la Cámara A, Gómez Mateos MA, Ferrando Vivas P, Baraínca Oyagüe MT, Abaitua Borda I, Posada de la Paz M. Prevalencia de factores de riesgo cardiovascular en una cohorte de afectados por el síndrome del aceite tóxico (Prevalence of cardiovascular risk factors in a cohort of affected by the toxic oil syndrome). Med Clin (Barc). 2003;121(11):405–407
  24. Abaitua Borda I, McPhilen R, Posada de la Paz M, et al. Toxic oil syndrome mortality: the first 13 years. Int J Epidemiol. 1998;27:1057–1063
  25. Pladevall M, Singal B, Keoki Williams L, et al. A single factor underlies the metabolic syndrome. A confirmatory factor analysis. Diabetes Care. 2006;29:113–122
  26. Keil U, Kulusama K for the WHO MONICA Project. WHO MONICA Project: risk factors. Int J Epidemiol. 1989;18:S46–S55
  27. Gómez de la Cámara A, Posada de la Paz M, Abaitua Borda I, et al. Health status measurements in Toxic Oil Syndrome. J Clin Epidemiol. 1998;51(10):867–873
  28. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;(19):2560–2572
  29. Gavin JR, Alberti KGMM, Davidson MB, et al. for the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (American Diabetes Association). Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183–1197
  30. Grundy SM, Becker D, Clark LT, et al. for the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
  31. Martín-Aragón E, Vioque J, Asensio L, Guillén M, Quiles J, Hdez-Aguado I. Uso de la circunferencia de cintura para detectar sobrepeso y obesidad con riesgo aumentado de enfermedad (Use of waist circumference to detect overweight and obesity posing increased risk of disease). 19th Scientific Meeting of the Spanish Society of Epidemiology Gac Sanit. 2001;15:67;[Suppl. 2]
  32. The European Group for the Study of Insulin Resistance (EGIR). The frequency of the WHO metabolic syndrome in European cohorts and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364–376
  33. The DECODE Study Group. Age and sex specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61–69
  34. López-Bescós L, Cosín J, Elosua R. Prevalencia de angina y factores de riesgo cardiovascular en las diferentes comunidades autónomas de España: estudio PANES (Prevalence of angina pectoris and cardiovascular risk factors in different Spanish regions: the PANES study). Rev Esp Cardiol. 1999;52(12):1045–1056
  35. Mosquera JD, Brea AJ, Ramalle-Gómara E, et al. Prevalencia de los factores de riesgo cardiovascular en población adulta de Logroño, La Rioja (Prevalence of cardiovascular risk factors in an adult population in Logroño, Spain). Clin Invest Arterioscler. 2000;12(4):199–208
  36. Gordon T, Castelli WP, Hjortland SC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med. 1977;62:707–714
  37. Glueck CK, Fallat RW, Spadafora M. Longevity syndromes. Circulation. 1975;52(II):272
  38. Brewer HB. Increasing HDL cholesterol levels. N Engl J Med. 2004;350(15):1491–1494
  39. Nissen SE, Tsunoda T, Tuzcu EM. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–2300
  40. Brousseau ME, Schaefer EJ, Wolfe ML. Effects of an inhibitor of the Cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505–1515
  41. Molarius A, Seidell JC. Selection of anthropometric indicators for classification of abdominal fatness: a critical review. Int J Obes. 1998;22:719–727

☆ Grant support: This study was funded by the World Health Organization/Instituto de Salud Carlos III, Toxic Oil Syndrome Scientific Committee and FIS, RETICS programme grant REpIER G03/123.

PII: S0953-6205(07)00230-0

doi: 10.1016/j.ejim.2007.04.018

European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 32-39 , January 2008

Article Tools

* Image Usage & Resolution